Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

By N. Hanna, F. Shepherd, F. Fossella, J. R. Pereira, F. de Marinis, J. von Pawel, U. Gatzemeier, T. Tsao, M. Pless, T. Muller and 10 more. Journal of Clinical Oncology, 2004

2,473 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/520d59d1148301d322b38588f422a59adf120b1d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Padmanee Sharma
2. James P. Allison
3. William Pao
4. Jie Yang
5. K. Kerr
6. M. Hellmann
7. S. Rosenberg
8. Lieping Chen

In Pulmonary and Respiratory Medicine

1. B. Hughes
2. B. Chan
3. L. Sequist
4. William Pao

Citations in the corpus

• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013, neutral): “Upper respiratory infection† 44 (26) 0 22 (13) 1 (<1)”
• Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. (2006, background): “Selected second- and third-line treatment strategies, currently single-agent regimens, can further improve survival duration [16, 17].”
• Reinforcement learning design for cancer clinical trials (2009, neutral): “The choice of agent also depends on many factors, including the patient's number of prior regimens, response to prior chemotherapy, the risk for neutropenia, EGFR expression, and patient preference [42,43,44,45].”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Pemetrexed demonstrated comparable OS to docetaxel in a randomised phase III trial but had a more favourable toxicity profile, with lower rates of neutropaenia, alopaecia and gastrointestinal events [156].”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Both docetaxel (70) and pemetrexed (71) are approved active agents in the second-line setting, but more therapeutic options were needed, especially for those unable to have further chemotherapy.”
• Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “Standard chemotherapies in this subgroup of patients have been associated with response rates of up to 10% (Hanna et al., 2004).”
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (2015, neutral): “Any event 76 (58) 9 (7) 111 (86) 71 (55)”